The impact of histologic tumor response on survival of patients treated with neoadjuvant mFOLFOX6 plus bevacizumab for the synchronous liver metastases from colorectal cancer.

被引：3
|
作者：
Katayose, Yu
Ishida, Kazuyuki
Nakagawa, Kei
Yamauchi, Junichiro
Oikawa, Masaya
Sakurai, Naoki
Musha, Hiroaki
Shimamura, Hiromune
Miura, Koh
Motoi, Fuyuhiko
Egawa, Shinichi
Unno, Michiaki
机构：
[1] Tohoku Univ, Grad Sch Med, Div Integrated Surg & Oncol, Sendai, Miyagi 980, Japan
[2] Iwate Med Univ, Dept Mol Diagnosit Pathol, Morioka, Iwate 020, Japan
[3] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[4] Sendai Open Hosp, Sendai, Miyagi, Japan
[5] Yamagata Prefectural Cent Hosp, Yamagata, Japan
[6] Tohoku Rosai Hosp, Sendai, Miyagi, Japan
[7] Sendai Med Ctr, Sendai, Miyagi, Japan
[8] Tohoku Univ, Grad Sch Med, Div Hepatobiliary & Pancreat Surg, Sendai, Miyagi 980, Japan
[9] Tohoku Univ, Grad Sch Med, Dept Surg, Sendai, Miyagi 980, Japan
[10] Tohoku Univ, Int Res Inst Disaster Sci, Sendai, Miyagi 980, Japan
[11] Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
625
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'
    Bibeau, F.
    Gil, H.
    Castan, F.
    Boissiere-Michot, F.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 3127 - 3129
  • [32] Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab’
    F Bibeau
    H Gil
    F Castan
    F Boissière-Michot
    British Journal of Cancer, 2013, 109 : 3127 - 3129
  • [33] Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
    Lima, Caio M. Rocha
    Bayraktar, Soley
    Flores, Aurea M.
    MacIntyre, Jessica
    Montero, Alberto
    Baranda, Joaquina C.
    Wallmark, John
    Portera, Chia
    Raja, Rajiv
    Stern, Howard
    Royer-Joo, Stephanie
    Amler, Lukas C.
    CANCER INVESTIGATION, 2012, 30 (10) : 727 - 731
  • [34] A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)
    Hiroyuki Uetake
    Masamichi Yasuno
    Megumi Ishiguro
    Shingo Kameoka
    Yasuhiro Shimada
    Keiichi Takahashi
    Toshiaki Watanabe
    Kei Muro
    Hideo Baba
    Junji Yamamoto
    Nobuyuki Mizunuma
    Hiroshi Tamagawa
    Izumi Mochizuki
    Yusuke Kinugasa
    Takashi Kikuchi
    Kenichi Sugihara
    Annals of Surgical Oncology, 2015, 22 : 908 - 915
  • [35] A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)
    Uetake, Hiroyuki
    Yasuno, Masamichi
    Ishiguro, Megumi
    Kameoka, Shingo
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Watanabe, Toshiaki
    Muro, Kei
    Baba, Hideo
    Yamamoto, Junji
    Mizunuma, Nobuyuki
    Tamagawa, Hiroshi
    Mochizuki, Izumi
    Kinugasa, Yusuke
    Kikuchi, Takashi
    Sugihara, Kenichi
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (03) : 908 - 915
  • [36] A multicenter phase II trial of mFOLFOX6 plus bevacizumab as treatment for liver-only metastases from colorectal cancer unsuitable for upfront resection (TRICC0808): Final analysis for survival.
    Tamagawa, Hiroshi
    Uetake, Hiroyuki
    Ishiguro, Megumi
    Mizunuma, Nobuyuki
    Kinugasa, Yusuke
    Mochizuki, Izumi
    Hamaguchi, Tetsuya
    Hasegawa, Junichi
    Katsumata, Kenji
    Ishibashi, Keiichiro
    Ogata, Yutaka
    Takii, Yasumasa
    Ooshiro, Mitsuru
    Kagimura, Tatsuo
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first
    C. Lim
    A. Doussot
    M. Osseis
    F. Esposito
    C. Salloum
    J. Calderaro
    C. Tournigand
    D. Azoulay
    Clinical and Translational Oncology, 2018, 20 : 1274 - 1279
  • [38] Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first
    Lim, C.
    Doussot, A.
    Osseis, M.
    Esposito, F.
    Salloum, C.
    Calderaro, J.
    Tournigand, C.
    Azoulay, D.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (10): : 1274 - 1279
  • [39] A phase II study of neoadjuvant chemotherapy with bevacizumab plus mFOLFOX6 for resectable synchronous liver metastasis (SLM) from colorectal cancer: The first report of the Miyagi Hepato-Biliary Pancreatic Clinical Oncology Group.
    Katayose, Yu
    Yamauchi, Junichiro
    Oikawa, Masaya
    Sakurai, Naoki
    Musya, Hiroaki
    Shimamura, Hiromune
    Miura, Koh
    Nakagawa, Kei
    Egawa, Shinichi
    Unno, Michiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [40] mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival
    Yasuno, Masamichi
    Uetake, Hiroyuki
    Ishiguro, Megumi
    Mizunuma, Nobuyuki
    Komori, Takamichi
    Miyata, Go
    Shiomi, Akio
    Kagimura, Tatsuo
    Sugihara, Kenichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) : 516 - 525
12345